100% of every donation goes directly to pancreatic cancer research.

Research Awards Listing

Research follows dollars, and The Lustgarten Foundation believes that increasing funds for pancreatic cancer research will translate into enhanced patient care, and ultimately, a cure.

The Lustgarten Foundation firmly believes that increasing funds for pancreatic cancer research is the surest path to improved patient care and eventually, to a cure. To date, we have committed nearly $120 million to providing the best and brightest minds with the resources to pursue the study and eradication of the disease.

View Award Listings by Year

2014  |  2013  |  2012  |  2011  |  2010  | 2009  |  2008  | 2007  |  2006  |  2005  |  2004  |  2003  |  2002  |  2001  |  2000-1998

2011 Research Grants

Baylor College of Medicine
Kenneth Scott, Ph.D.
In Vivo Positive Selection Screening for Somatic MutationDrivers of Pancreatic Cancer Metastasis

Columbia University
Kenneth Olive, Ph.D.
Preclinical Evaluation of the Mutant-Ras Synthetic Lethal Drug MEII

Johns Hopkins Medical Institutions
Ralph Hruban, M.D. 
Familial Project Part 2

Johns Hopkins Medical Institutions
Daniel Laheru,M.D., Ana De Jesus-Acosta,M.D.
Phase II study of Gemcitabine and Abraxane in Combination with Vismodegib (GDC-0449), a Hedgehog Pathway Inhibitor, in Patients with Previously Untreated Mestastatic Adenocarcinnoma of the Pancreas. 

Johns Hopkins Medical Institutions
Anne Le, Ph.D.
Targeting Pancreatic Cancer Metabolism

Johns Hopkins Medical Institutions
Lei Zheng,M.D., Ph.D.
Annexin A2, a Newly Identified Pro-Metastasis Tumor Antigen as a Target for Pancreatic Cancer Therapy

Massachusetts General Hospital
Jeff Engleman, M.D., Ph.D.
Identification of Novel KRAS-directed Targeted Therapy Combination Strategies for Pancreatic Cancer.

Massachusetts General Hospital
Massachusetts Institute of Technology
Rakesh Jain, Ph.D., Robert Langer, Ph.D.
Seeking to Improve Drug Delivery in Pancreatic Cancer by Widenine Blood Vessels Surrounding the Cancer to More Effective Access the Tumor.

Massachusetts Institute of Technology
Dana-Farber Cancer Institute
Hidde Ploegh, Ph.D., Kai Wucherpfenning,M.D., Ph.D., Christopher Love, Ph.D.
Seeks to Develop a Mouse Model that Would Mimic the Human Immune System, Which Could then be used as a Tool to help Develop Immunotherapy Agents for Human Trails.

Massachusetts Institute of Technology
Matthew Vander Heiden, M.D., Ph.D.
Metabolism and Pancreatic Cancer Pathogenesis: A Multi-Institutional Approach to Define Novel Screening Modalities and Treatments for Pancreatic Cancer.

Memorial Sloan Kettering Cancer Center
Eileen O'Reilly, M.D.
A Phase II Study to try a Drug Combination in BRCA Mutated Pancreatic Cancers that was Successful in BRCA Mutated Breast Cancers.

SUNY Upstate Medical University
Eileen Friedman, Ph.D.
A ROS- Controlling Kinase in Pancreatic Cancer.

The Regents of the University of California
Michael Karin, Ph.D.
Pathogehic Functions of IKKa, p62 and Impaired Autophagy in Pancreatic Cancer.

University of California, San Diego
Judith Varner, Ph.D.
Selective Inhibitors of Inflammation as a New Therapeutic Approach for Pancreatic Cancer.

University of Colorado
Johns Hopkins Medical Institutions
Wells Messersmith, M.D., Anirban Maitre, M.B.B.S.
A Phase II Study to Assess a New Drug for Pancreatic Cancer made by Roche.

Univesity of North Carolina
Channing Der, Ph.D.
Study Drug Combinations Surrounding the ERK and K-ras Pathways in a Novel Cell Culture System (3DSpheroids) to Identify Promising Drug Combinations that can be used in Clinical Trials.

University of Texas M.D. Anderson Cancer Center
Gauri Varadachary, M.B.B.S., M.D.
A Novel Preoperative Platform in Pancreatic Cancer for Mechanistic Studies

Washington University
David DeNardo, Ph.D.
Targeting Tumor-Associated Macrophages to Overcome Chemotherapeutic Resistance in Pancreatic Cancer.

2015 website development and design sponsored by Celgene

1111 Stewart Avenue, Bethpage, New York 11714
Toll Free: 1-866-789-1000 P: 516-803-2304 F: 516-803-2303